{"result": {"id": "d52163b9-b684-4948-b9e9-cc3ffc80b6d0", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>STATINS<|>ORGANIZATION<|>Statins are the first-line drugs for lowering LDL-C to reduce ASCVD risk\")  \n##  \n(\"entity\"<|>ISCHEMIC STROKE<|>EVENT<|>A type of ASCVD event caused by blocked blood flow to the brain\")  \n##  \n(\"entity\"<|>MYOCARDIAL INFARCTION<|>EVENT<|>A type of ASCVD event involving heart tissue damage due to blocked blood flow\")  \n##  \n(\"entity\"<|>PERIPHERAL VASCULAR DISEASE<|>EVENT<|>A type of ASCVD affecting blood vessels outside the heart and brain\")  \n##  \n(\"entity\"<|>REVASCULARIZATION<|>EVENT<|>A surgical procedure to restore blood flow, considered an ASCVD event\")  \n##  \n(\"entity\"<|>AMPUTATION<|>EVENT<|>A severe consequence of peripheral vascular disease, classified as ASCVD\")  \n##  \n(\"entity\"<|>ACUTE CORONARY SYNDROME<|>EVENT<|>A severe ASCVD manifestation including heart attacks and unstable angina\")  \n##  \n(\"entity\"<|>PANCREATITIS<|>EVENT<|>A risk associated with very high triglyceride levels (≥5 mmol/L)\")  \n##  \n(\"relationship\"<|>STATINS<|>LDL-C<|>Statins are the primary treatment for reducing LDL-C levels<|>9\")  \n##  \n(\"relationship\"<|>ISCHEMIC STROKE<|>ASCVD<|>Ischemic stroke is a component of ASCVD events<|>9\")  \n##  \n(\"relationship\"<|>MYOCARDIAL INFARCTION<|>ASCVD<|>Myocardial infarction is a key ASCVD event<|>9\")  \n##  \n(\"relationship\"<|>PERIPHERAL VASCULAR DISEASE<|>ASCVD<|>Peripheral vascular disease is included in ASCVD classification<|>9\")  \n##  \n(\"relationship\"<|>REVASCULARIZATION<|>ASCVD<|>Revascularization history indicates prior ASCVD<|>8\")  \n##  \n(\"relationship\"<|>AMPUTATION<|>PERIPHERAL VASCULAR DISEASE<|>Amputation may result from advanced peripheral vascular disease<|>8\")  \n##  \n(\"relationship\"<|>ACUTE CORONARY SYNDROME<|>ASCVD<|>Acute coronary syndrome represents severe ASCVD manifestations<|>9\")  \n##  \n(\"relationship\"<|>PANCREATITIS<|>TRIGLYCERIDE RICH LIPOPROTEINS (TRL)<|>Extremely high triglyceride levels (via TRL) increase pancreatitis risk<|>7\")  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558683, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 633, "prompt_tokens": 3208, "total_tokens": 3841, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3136}, "prompt_cache_hit_tokens": 3136, "prompt_cache_miss_tokens": 72}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ASCVD事件包括心肌梗 死史、缺血性脑卒中史、有症状的周围血管病变、既往接受过血运重建 或截肢等。\n　　　降 LDL-C治疗的药物选择 :降 LDL-C药物治疗 , 首选他汀类药物 。启动药物治疗 4~6周后复查血脂 , LDL-C达到目标值后继续维持长期治疗 。对中等强 度他汀类药物治疗后 LDL-C不能达标者可加用胆固 醇吸收抑制剂依折麦布 。最大耐受剂量他汀类药物和 依折麦布治疗后 LDL-C仍不达标的急性冠脉综合征 患者 ,可联用 PCSK9抑制剂。\n　　　降甘油三酯治疗 : 临床发现 ,积极控制血 LDL-C 之后 ,ASCVD残余风险仍存在 。 富含甘油三酯脂蛋  白颗粒(triglyceride rich lipoproteins,TRL) 已被证实  具有显著致动脉粥样硬化作用 。 临床上 TRL水平可  以通过甘油三酯水平来评估 。轻中度血甘油三酯增  高 , ASCVD 风 险 增 加 , 当 甘 油 三 酯 ≥ 5 mmol/L (443mg/dL) 时 ,胰腺炎风险持续增长 。 因此 ,高血压  患者 ,血甘油三酯 >2.3 mmol/L(200mg/dL) 时 ,首  先启用他汀类药物降低 ASCVD风险 ,若 LDL-C达标  后 ,甘油三酯仍在 2.3~ 5.6 mmol/L者 ,可考虑加用  贝特类药物或大剂量二十碳五烯酸乙酯(4g/d) 。对  甘油三酯 ≥5.7 mmol/L患者 ,若为 ASCVD低危风  险 ,需立即启用贝特类或 Omega-3多不饱和脂肪酸 ,  若是 ASCVD高风险患者 ,则在优化他汀类药物为基  础的降胆固醇治疗基础上加用贝特类或 Omega-3多  不饱和脂肪酸。\n\n\n　　　高血压患者应提高降压联合降脂治疗的长期依从 性 ,才能获得 ASCVD防控的最大效益。\n5.3.3  抗血小板治疗\n\n要点 5J  抗血小板治疗\n　　　·高血压伴有缺血性心脑血管疾病的患者 ,推荐 进行抗血小板治疗( Ⅰ ,A) 。\n　　　·具有 ASCVD高危且合并至少 1项风险增强 因素但无高出血风险的 40~70岁的患者 ,可考虑应 用低剂量阿司匹林进行 ASCVD一级预防( Ⅱb,B) 。\n　　　· ASCVD风险中低危患者 , 以及年龄 <40岁 或>70岁的患者 ,不推荐采用低剂量阿司匹林进行 ASCVD一级预防( Ⅲ ,C) 。\n\n　　抗血小板治疗在心脑血管疾病二级预防中的作用 已被大量临床研究证实 ,可有效降低心血管事件风险 19%~25% ,其中非致死性心肌梗死下降 1/3,非致\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>ASCVD<|>EVENT<|>ASCVD refers to atherosclerotic cardiovascular disease, including myocardial infarction, ischemic stroke, symptomatic peripheral vascular disease, and history of revascularization or amputation\")  \n##  \n(\"entity\"<|>LDL-C<|>EVENT<|>LDL-C stands for low-density lipoprotein cholesterol, a target for lipid-lowering therapy to reduce ASCVD risk\")  \n##  \n(\"entity\"<|>TRIGLYCERIDE RICH LIPOPROTEINS (TRL)<|>EVENT<|>TRL are lipoprotein particles associated with increased atherosclerosis risk, assessed via triglyceride levels\")  \n##  \n(\"entity\"<|>PCSK9 INHIBITOR<|>ORGANIZATION<|>PCSK9 inhibitors are a class of drugs used to lower LDL-C in patients not achieving targets with statins and ezetimibe\")  \n##  \n(\"entity\"<|>EZETIMIBE<|>ORGANIZATION<|>Ezetimibe is a cholesterol absorption inhibitor used alongside statins for LDL-C reduction\")  \n##  \n(\"entity\"<|>FIBRATES<|>ORGANIZATION<|>Fibrates are drugs used to lower triglycerides, particularly in patients with elevated levels despite LDL-C control\")  \n##  \n(\"entity\"<|>OMEGA-3 POLYUNSATURATED FATTY ACIDS<|>ORGANIZATION<|>Omega-3 fatty acids are used to manage high triglyceride levels, especially in ASCVD high-risk patients\")  \n##  \n(\"entity\"<|>ASPIRIN<|>ORGANIZATION<|>Low-dose aspirin is recommended for ASCVD prevention in high-risk patients without high bleeding risk\")  \n##  \n(\"relationship\"<|>ASCVD<|>LDL-C<|>Lowering LDL-C is a primary strategy to reduce ASCVD risk<|>8\")  \n##  \n(\"relationship\"<|>TRIGLYCERIDE RICH LIPOPROTEINS (TRL)<|>ASCVD<|>Elevated TRL levels contribute to residual ASCVD risk even after LDL-C control<|>7\")  \n##  \n(\"relationship\"<|>PCSK9 INHIBITOR<|>LDL-C<|>PCSK9 inhibitors are used when LDL-C remains high despite statin and ezetimibe therapy<|>9\")  \n##  \n(\"relationship\"<|>EZETIMIBE<|>LDL-C<|>Ezetimibe is added to statins to further reduce LDL-C levels<|>8\")  \n##  \n(\"relationship\"<|>FIBRATES<|>TRIGLYCERIDE RICH LIPOPROTEINS (TRL)<|>Fibrates are used to lower elevated triglycerides associated with TRL<|>7\")  \n##  \n(\"relationship\"<|>OMEGA-3 POLYUNSATURATED FATTY ACIDS<|>TRIGLYCERIDE RICH LIPOPROTEINS (TRL)<|>Omega-3 fatty acids help manage high triglyceride levels linked to TRL<|>7\")  \n##  \n(\"relationship\"<|>ASPIRIN<|>ASCVD<|>Aspirin is used for primary and secondary prevention of ASCVD in high-risk patients<|>8\")  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_fffce549ac19c7ac4ef6616b0a8e3811be758255eadbbe7ac88086bfcd4118bd_v2"}